300357.SZ
我武生物
SZSE · Healthcare · C 制造业 · CN
CNY 23.26
−5.64%Year over year
Reported trailing growth
- Revenue
- +15.9%
- EBITDA
- —
- EBIT
- +33.0%
- EPS
- +35.2%
- Free cash flow
- +55.1%
- Operating cash flow
- +28.8%
Forward estimates
Based on analyst estimates
- Revenue
- -7.5%
- EBITDA
- +20.4%
- EPS
- +4.5%
Three-year CAGR
- Revenue
- +5.8%
- EBITDA
- +5.4%
- EBIT
- +3.4%
- Net income
- +3.0%
- EPS
- +3.0%
- Free cash flow
- +21.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026